A phase 3 CAR-T cell therapy for bone marrow cancers (myelomas) cut death rates by more than half. Bristol Myers Squibb is planning a supplemental application to the FDA this year for approval.
Read more!
You can also learn more about how CAR-T cell therapy works in one of Rob’s previous videos: Gene Therapy Breakdown.